<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447172</url>
  </required_header>
  <id_info>
    <org_study_id>INN-TOP-005</org_study_id>
    <nct_id>NCT02447172</nct_id>
  </id_info>
  <brief_title>Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers</brief_title>
  <acronym>COACT-2</acronym>
  <official_title>A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With an Infected Foot Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innocoll</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innocoll</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, randomized, controlled, blinded, multicenter study conducted in 3 parallel&#xD;
      cohorts of diabetic patients with at least 1 infected foot ulcer. Patients will be randomized&#xD;
      to receive 1 of 3 study treatments; systemic antibiotic therapy and standard ulcer care with&#xD;
      either (A) daily application of a gentamicin-sponge, (B) daily application of a&#xD;
      placebo-sponge or (C) no-sponge, in the ratio 2:1:1. Patients will be treated for&#xD;
      approximately 28 days and return to the clinic weekly for safety and efficacy assessments.&#xD;
      After completing treatment, patients will return to the clinic for scheduled follow-up visits&#xD;
      approximately 10, 30, 60 and 90 days after treatment is stopped.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, randomized, controlled, blinded, multicenter study conducted in 3 parallel&#xD;
      cohorts of diabetic patients with at least 1 infected foot ulcer. Patients will be randomized&#xD;
      using an electronic randomization system to receive 1 of 3 study treatments; systemic&#xD;
      antibiotic therapy and standard ulcer care with either (A) daily application of a&#xD;
      gentamicin-sponge, (B) daily application of a placebo-sponge or (C) no-sponge, in the ratio&#xD;
      2:1:1. The investigator will be blinded to the patient's treatment group assignment and&#xD;
      patients randomized to one of the 2 sponge groups will be blinded as to whether the sponge is&#xD;
      active or placebo.&#xD;
&#xD;
      If a patient has multiple infected ulcers, the assigned treatment will be administered to all&#xD;
      infected ulcers. The investigator will determine the highest severity ulcer to be used for&#xD;
      all efficacy evaluations and will also determine the size and number of sponges (up to 4)&#xD;
      that a patient will use in order to completely cover all infected ulcers. The investigator&#xD;
      will prescribe an empiric systemic antibiotic therapy based on protocol instructions.&#xD;
&#xD;
      Patients will be treated for approximately 28 days and return to the clinic weekly for safety&#xD;
      and efficacy assessments. The investigator will stop study treatment if a patient achieves&#xD;
      clinical cure by or after the 3rd treatment visit (approximately study day 15). After&#xD;
      completing treatment, patients will return to the clinic for scheduled follow-up visits or&#xD;
      until ulcer closure. The final efficacy assessments used in the primary efficacy analyses&#xD;
      will be obtained at the first follow-up visit approximately 10 days after treatment is&#xD;
      stopped. The remaining follow-up visits will occur at approximately 30, 60 and 90 days after&#xD;
      treatment is stopped when patients will be assessed for ulcer closure and any re-infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Patients With a Clinical Outcome of Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection)</measure>
    <time_frame>approximately 10 days after end of treatment</time_frame>
    <description>The primary efficacy variable is the percent of patients with a clinical outcome of clinical cure (Resolution of all clinical signs and symptoms of infection) at F/U visit 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Re-infections</measure>
    <time_frame>up to 90 days after treatment stopped</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Response</measure>
    <time_frame>up to 90 days after treatment stopped</time_frame>
    <description>Time in Days to Clinical Cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects That Had an Amputation Associated With the Target Ulcer</measure>
    <time_frame>up to 90 days after treatment stopped</time_frame>
    <description>Modified Intent-to-Treat Population - Percent of subjects that had an amputation associated with the target ulcer</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">524</enrollment>
  <condition>Foot Ulcer, Diabetic</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Gentamicin sponge group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo sponge group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No sponge group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin Collagen sponge</intervention_name>
    <description>Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
    <arm_group_label>Gentamicin sponge group</arm_group_label>
    <other_name>Cogenzia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo sponge</description>
    <arm_group_label>Placebo sponge group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria.&#xD;
&#xD;
          -  Has at least 1 skin ulcer located on or below the malleolus that presents with the&#xD;
             following clinical manifestations of a moderate or severe infection based on the&#xD;
             Infectious Disease Society of America guidelines for the &quot;Diagnosis and Treatment of&#xD;
             Diabetic Foot Infections&quot; (CID 2012; 54:132-173) (IDSA guidelines):&#xD;
&#xD;
          -  has ≥ 2 manifestations of inflammation (local swelling or induration, erythema, local&#xD;
             tenderness or pain, local warmth, purulent discharge (thick, opaque to white or&#xD;
             sanguineous secretion)&#xD;
&#xD;
          -  has ≥ 1 of the following characteristics: erythema &gt; 2cm, or involving structures&#xD;
             deeper than skin and subcutaneous tissues (e.g. abscess, osteomyelitis, septic&#xD;
             arthritis, fasciitis) For patients with multiple infected ulcers, the ulcer with the&#xD;
             highest Diabetic Foot Infection Wound score (DFI score) must be on or below the&#xD;
             malleolus and all infected ulcers must be completely coverable using no more than 4&#xD;
             sponges (sponges cannot be cut).&#xD;
&#xD;
          -  Has documented adequate arterial perfusion in the affected limb(s) (either palpable&#xD;
             dorsalis pedis and posterior tibial pulses, or normal Doppler wave forms, a toe blood&#xD;
             pressure ≥ 45 mm Hg or participation is approved by a vascular surgeon)&#xD;
&#xD;
          -  Has received appropriate surgical intervention to remove all necrotic and infected&#xD;
             bone if diagnosed with osteomyelitis.&#xD;
&#xD;
          -  Has received appropriate surgical debridement to remove all gangrenous tissue.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Has a known history of hypersensitivity to gentamicin (or other aminoglycosides).&#xD;
&#xD;
          -  Has a known or suspected hypersensitivity to bovine collagen.&#xD;
&#xD;
          -  Has an ulcer infection which, based upon the patient's known history of&#xD;
             hypersensitivity and/or as otherwise in the opinion of the investigator, cannot be&#xD;
             adequately treated with at least one of the empiric systemic antibiotic regimens&#xD;
             allowed by this protocol.&#xD;
&#xD;
          -  Has an ulcer associated with prosthetic material or an implanted device.&#xD;
&#xD;
          -  Has received any systemic or topical antibiotic therapy for any reason within 7 days&#xD;
             of randomization unless it was administered to specifically treat the infected&#xD;
             ulcer(s) and only within 36 hours of randomization.&#xD;
&#xD;
          -  Requires or is likely to require treatment with any concomitant topical product or&#xD;
             wound therapy before the first follow-up study visit.&#xD;
&#xD;
          -  Is severely immunocompromised, or likely to become severely immunocompromised during&#xD;
             the study, in the opinion of the investigator.&#xD;
&#xD;
          -  Has a history of myasthenia gravis or other neurological condition where gentamicin&#xD;
             use is contraindicated as determined by the investigator.&#xD;
&#xD;
          -  Has a history of epilepsy.&#xD;
&#xD;
          -  Has a history of alcohol or substance abuse in the past 12 months.&#xD;
&#xD;
          -  Has an uncontrolled illness that, in the opinion of the investigator, is likely to&#xD;
             cause the patient to be withdrawn from the trial or would otherwise interfere with&#xD;
             interpreting the results of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nigel Jones</last_name>
    <role>Study Director</role>
    <affiliation>Vice President, Global Clinical Operations, Innocoll Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cowra</city>
        <state>New South Wales</state>
        <zip>2794</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring Hill</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liége</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pellenberg</city>
        <zip>3212</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 6</city>
        <zip>169 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Třinec</city>
        <zip>739 61</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zlín</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>København</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Mergentheim</city>
        <state>Baden-Württemberg</state>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fulda</city>
        <state>Hessen</state>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bosenheim</city>
        <state>Reinland-Pfalz</state>
        <zip>55545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01279</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pirna</city>
        <state>Sachsen</state>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hatvan</city>
        <zip>3000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orosháza</city>
        <zip>5900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szekszárd</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sátoraljaújhely</city>
        <zip>3980</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campobasso</city>
        <state>CB</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abano Terme</city>
        <state>PD</state>
        <zip>35031</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pistoia</city>
        <state>Point</state>
        <zip>51100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bassano del Grappa</city>
        <state>VI</state>
        <zip>36061</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almere</city>
        <zip>1315RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <zip>5631BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>the Hague</city>
        <zip>2526HW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <zip>3582KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wrocław</city>
        <state>Lower Silesia</state>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chorzow</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Czestochowa</city>
        <zip>42-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>30-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>90-553</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznań</city>
        <zip>616-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Studzionka</city>
        <zip>43-245</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-541</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zabrze</city>
        <zip>41-819</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <zip>81369</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <zip>83103</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nitra</city>
        <zip>95001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trenćín</city>
        <zip>91171</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trnava</city>
        <zip>917 75</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ľubochňa</city>
        <zip>034 91</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Sebastian</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>23922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manises</city>
        <state>Valencia</state>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradford</city>
        <zip>BD96RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burton on Trent</city>
        <zip>DE13 0RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coventry</city>
        <zip>CV22DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <zip>LA1 4RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merthyr</city>
        <zip>CF47 9DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stoke-on-Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <results_first_submitted>June 1, 2021</results_first_submitted>
  <results_first_submitted_qc>August 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2021</results_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gentamicin Sponge Group</title>
          <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin Collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
        </group>
        <group group_id="P2">
          <title>Placebo Sponge Group</title>
          <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching placebo sponge</description>
        </group>
        <group group_id="P3">
          <title>No Sponge Group</title>
          <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>protocol specific treatment unrelated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gentamicin Sponge Group</title>
          <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin Collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
        </group>
        <group group_id="B2">
          <title>Placebo Sponge Group</title>
          <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching placebo sponge</description>
        </group>
        <group group_id="B3">
          <title>No Sponge Group</title>
          <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="262"/>
            <count group_id="B2" value="130"/>
            <count group_id="B3" value="132"/>
            <count group_id="B4" value="524"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="10.68"/>
                    <measurement group_id="B2" value="62.7" spread="10.55"/>
                    <measurement group_id="B3" value="63.0" spread="10.81"/>
                    <measurement group_id="B4" value="62.4" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Patients With a Clinical Outcome of Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection)</title>
        <description>The primary efficacy variable is the percent of patients with a clinical outcome of clinical cure (Resolution of all clinical signs and symptoms of infection) at F/U visit 1</description>
        <time_frame>approximately 10 days after end of treatment</time_frame>
        <population>modified intent to treat consisted of randomized patients who received any dose of gentamicin-sponge or placebo-sponge or who were randomized to the nosponge arm, and who were not early-terminated for one treatment-unrelated reasons before F/U visit 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gentamicin Sponge Group</title>
            <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin Collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Sponge Group</title>
            <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching placebo sponge</description>
          </group>
          <group group_id="O3">
            <title>No Sponge Group</title>
            <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With a Clinical Outcome of Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection)</title>
          <description>The primary efficacy variable is the percent of patients with a clinical outcome of clinical cure (Resolution of all clinical signs and symptoms of infection) at F/U visit 1</description>
          <population>modified intent to treat consisted of randomized patients who received any dose of gentamicin-sponge or placebo-sponge or who were randomized to the nosponge arm, and who were not early-terminated for one treatment-unrelated reasons before F/U visit 1.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Re-infections</title>
        <time_frame>up to 90 days after treatment stopped</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Gentamicin Sponge Group</title>
            <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin Collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Sponge Group</title>
            <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching placebo sponge</description>
          </group>
          <group group_id="O3">
            <title>No Sponge Group</title>
            <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Re-infections</title>
          <population>Modified Intent-to-Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Clinical Response</title>
        <description>Time in Days to Clinical Cure</description>
        <time_frame>up to 90 days after treatment stopped</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Gentamicin Sponge Group</title>
            <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin Collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Sponge Group</title>
            <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching placebo sponge</description>
          </group>
          <group group_id="O3">
            <title>No Sponge Group</title>
            <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinical Response</title>
          <description>Time in Days to Clinical Cure</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="NA" upper_limit="NA">limits of the 95% Confidence Interval were not estimable due to insufficient number of events</measurement>
                    <measurement group_id="O2" value="8" lower_limit="NA" upper_limit="NA">limits of the 95% Confidence Interval were not estimable due to insufficient number of events</measurement>
                    <measurement group_id="O3" value="8" lower_limit="NA" upper_limit="NA">limits of the 95% Confidence Interval were not estimable due to insufficient number of events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects That Had an Amputation Associated With the Target Ulcer</title>
        <description>Modified Intent-to-Treat Population - Percent of subjects that had an amputation associated with the target ulcer</description>
        <time_frame>up to 90 days after treatment stopped</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gentamicin Sponge Group</title>
            <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin Collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Sponge Group</title>
            <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching placebo sponge</description>
          </group>
          <group group_id="O3">
            <title>No Sponge Group</title>
            <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects That Had an Amputation Associated With the Target Ulcer</title>
          <description>Modified Intent-to-Treat Population - Percent of subjects that had an amputation associated with the target ulcer</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gentamicin Sponge Group</title>
          <description>Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Gentamicin Collagen sponge: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)</description>
        </group>
        <group group_id="E2">
          <title>Placebo Sponge Group</title>
          <description>Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.&#xD;
Placebo: Matching placebo sponge</description>
        </group>
        <group group_id="E3">
          <title>No Sponge Group</title>
          <description>Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>thrombocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>generalixed oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>impaired healing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infected skin ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="260"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>osteomyelitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>abscess limb</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>diabetic gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>necrotising fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>superinfection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>vascular graft complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>vascular injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>c-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>investigation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>neuropathic arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>delirium tremens</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>diabetic nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>nocturnal dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>diabetic foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>skin necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>poor peripheral circulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>shock haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>vascular occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="129"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="260"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="260"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infected skin ulcer</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="260"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="129"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="260"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Urinary track Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="260"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin ulcer</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="260"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="129"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>skin ulcer</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="260"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="129"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>results of the multicenter study had to be published prior to the publication of any site specific data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charlene A. Tucker MS, Executive Director, Medical Writing and Document Management</name_or_title>
      <organization>Innocoll</organization>
      <phone>484-406-5211</phone>
      <email>ctucker@innocoll.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

